×
Skye Bioscience Operating Expenses 2013-2024 | SKYE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Skye Bioscience operating expenses from 2013 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Skye Bioscience Operating Expenses 2013-2024 | SKYE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Skye Bioscience operating expenses from 2013 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.9B
Regeneron Pharmaceuticals (REGN)
$125.5B
Vertex Pharmaceuticals (VRTX)
$122.4B
Gilead Sciences (GILD)
$104.4B
Bristol Myers Squibb (BMY)
$100.8B
CSL (CSLLY)
$96.8B
GSK (GSK)
$87.9B
Alnylam Pharmaceuticals (ALNY)
$35.1B
Argenex SE (ARGX)
$31.6B
Biogen (BIIB)
$28.8B
BioNTech SE (BNTX)
$27.5B
Moderna (MRNA)
$26.9B
Illumina (ILMN)
$20.9B
BeiGene (BGNE)
$19.2B
Genmab (GMAB)
$17.3B
BioMarin Pharmaceutical (BMRN)
$13.5B
Vaxcyte (PCVX)
$13B
Exact Sciences (EXAS)
$12.8B
Incyte (INCY)
$12.6B
Insmed (INSM)
$12.5B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.4B
Bio-Rad Laboratories (BIO.B)
$9.1B
Legend Biotech (LEGN)
$9.1B
Roivant Sciences (ROIV)
$8.9B
Ascendis Pharma (ASND)
$8.7B
Repligen (RGEN)
$8B
Halozyme Therapeutics (HALO)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.9B